Lack of influence of the anabolic steroid nandrolondecanoate on bone metabolism

1982 ◽  
Vol 101 (1) ◽  
pp. 140-143 ◽  
Author(s):  
J. W. J. Bijlsma ◽  
S. A. Duursma ◽  
R. Bosch ◽  
O. Huber

Abstract. Eleven male patients with rheumatoid arthritis were treated with the anabolic steroid nandrolondecanoate and parameters of calcium and bone metabolism were studied. No changes were found in the concentrations of calcium, phosphorus or hydroxyproline in serum and urine (corrected for the creaturia). A significant decrease (P < 0.01) was observed in the levels of alkaline phosphatase, but this was attributed to a change in liver enzymes, because the gamma glutamyl transpeptidase fell. Acid phosphatase levels showed an increase, possibly as a result of an effect of nandrolondecanoate on the prostate. No change was found during treatment in the serum levels of parathyroid hormone, calcitonin, 25 hydroxyvitamin D, 24,25 dihydroxyvitamin D and 1.25 dihydroxyvitamin D. A seasonal fluctuation was observed for 25 hydroxyvitamin D and 24,25 dihydroxyvitamin D, but not for 1,25 dihydroxyvitamin D. It was concluded that short-term treatment with the anabolic steroid nandrolondecanoate did not result in changes in parameters of calcium and bone metabolism.

2005 ◽  
Vol 11 (3) ◽  
pp. 266-271 ◽  
Author(s):  
M Soilu-Hänninen ◽  
L Airas ◽  
I Mononen ◽  
A Heikkilä ◽  
M Viljanen ◽  
...  

Past sun exposure and vitamin D supplementation have been associated with a reduction in the risk of MS. We measured the serum concentration of 25-hydroxyvitamin D (25[OH]D) at the time of MS diagnosis in 40 MS patients and 40 controls. We found no difference in the serum levels of 25(OH)D between MS patients and controls when all samples or samples obtained during winter months were compared, but MS patients had significantly lower serum 25(OH)D concentrations in June to September than the controls. The vitamin D stores were adequate for bone metabolism (> 37 nmol/L) in 70% of MS patients throughout the year and within the hypovitaminosis level (< 37 nmol/L) in 30% of MS patients at some time of the year. During MS-relapses, 25(OH)D levels were lower than in remission, but mostly within the reference range observed in relation with normal bone metabolism. We conclude that the vitamin D stores in most MS patients are adequate for their normal bone metabolism. However, lower vitamin D levels during MS relapses than in remission suggest that vitamin D could be involved in the regulation of the clinical disease activity of MS. The optimal serum levels of vitamin D for the regulation of immune responses remain to be determined.


1989 ◽  
Vol 17 (3) ◽  
pp. 226-242 ◽  
Author(s):  
E. Harju ◽  
R. Punnonen ◽  
R. Tuimala ◽  
J. Salmi ◽  
I. Paronen

The effects on general and bone metabolism of femoral neck fracture patients of 0.25 μg α-calcoid given orally twice daily ( n=9) and 25 μg calcitonin given subcutaneously 30 times ( n=10) in 10 weeks were studied against a control ( n=ll). Bone histology and histomorphometry showed non-age related osteoporosis in 30% and osteomalacia in 22% of the patients studied. Impaired serum vitamin D status was found in 47 – 88% of patients, secondary hyperparathyroidism and increased serum parathyroid hormone in 59% and decreased serum calcitonin levels in 69%. On histology, normal findings and non-age related osteoporosis on histology were associated with low serum levels of 25-hydroxyvitamin D3,1,25- and 24,25-dihydroxy vitamin D3. Very high serum levels of 1,25-dihydroxyvitamin D3 and low levels of 25-hydroxyvitamin D3 occurred in fracture patients with osteomalacia. Calcitonin improved calcium balance, reduced osteoporosis and increased the serum 1,25- and 24,25-dihydroxyvitamin D3 levels but had no effect on osteomalacia. Vitamin D reduced osteomalacia, slightly increased the serum 1,25-dihydroxyvitamin D3 concentration and decreased serum levels of parathyroid hormone. Both treatments gave a similar slight decrease in serum calcitonin concentrations. A mechanism of action for the treatments is suggested.


Cureus ◽  
2021 ◽  
Author(s):  
Manami Fujita-Yamashita ◽  
Koichiro Yamamoto ◽  
Hiroyuki Honda ◽  
Yoshihisa Hanayama ◽  
Kazuki Tokumasu ◽  
...  

1999 ◽  
Vol 55 (3) ◽  
pp. 1019-1027 ◽  
Author(s):  
Eiji Ishimura ◽  
Yoshiki Nishizawa ◽  
Masaaki Inaba ◽  
Naoki Matsumoto ◽  
Masanori Emoto ◽  
...  

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A272-A273
Author(s):  
Koichiro Yamamoto ◽  
Manami Fujita ◽  
Hiroyuki Honda ◽  
Yoshihisa Hanayama ◽  
Kazuki Tokumasu ◽  
...  

Abstract Vitamin D is obtained in the body by food intake or by production from 7-dehydrocholesterol by exposure of the skin to ultraviolet B radiation. It is first metabolized in the liver to 25-hydroxyvitamin D (25D), which is a major circulating metabolite. In the kidney, 25D is subsequently metabolized to the hormonally active form, 1,25-dihydroxyvitamin D (1,25D), via 1α-hydroxylase encoded by the CYP27B1 gene. 1,25D has a cellular effect through the vitamin D receptor, which leads to calcium absorption in the gut, bone metabolism, and parathyroid function. A recent study showed that a low vitamin D status is common worldwide and is associated with various diseases including kidney, heart, and liver failure, secondary hyperparathyroidism, osteomalacia, inflammatory bowel disease, granuloma-forming disorders (sarcoidosis and tuberculosis), and cancer. Vitamin D deficiency also increases the risks of falls, fractures, bone loss, sarcopenia, leading to worse outcomes of illness severity, morbidity, and mortality. The 1,25D/25D ratio is considered to be a useful tool for diagnosis of ocular sarcoidosis; however, its clinical utility and relevance to pathophysiology of evaluation of the ratio 1,25D/25D which indicates vitamin D activation have remained unknown. To clarify the clinical usefulness of markers for vitamin D activation, 87 patients in whom serum 25D and 1,25D level was measured were retrospectively reviewed in the present study. Data for 79 patients (33 males and 46 females) were analyzed after exclusion of 8 patients taking vitamin D. The median serum 1,25D/25D ratio was significantly lower in males than in females: 4.1 (IQR: 2.3–5.8) x 10−3 versus 6.8 (3.0–9.8) x 10−3. However, individual levels of 25D and 1,25D were not different in males and females. The major categories of main disorders were endocrine (30.6 %), inflammatory (18.5 %), and bone-related (16.7 %) disorders. The ratios of serum 1,25D/25D had significant negative correlations with femoral dual energy X-ray absorptiometry % young adult mean (DEXA %YAM) (R=-0.35) and lumbar DEXA %YAM (R=-0.32). Significant correlations were found between 1,25D/25D ratio and serum levels of inorganic phosphate (R=-0.34), intact parathyroid hormone (R=0.64) and alkaline phosphatase (R=0.46) in all patients. Of interest, the 1,25D/25D ratio had gender-specific characteristics: the ratio had a significant correlation with age in males (R=0.49), while it had a significant correlation with body mass index (BMI) in females (R=0.34). Collectively, the results revealed that the ratio of serum 1,25D/25D as a marker for activation of vitamin D had relevance to clinical parameters, especially bone turnover, with gender-specific features. It is suggested that the existence of a gender-specific difference of aging males and obese females regarding the activation of vitamin D that is functionally linked to bone metabolism.


1984 ◽  
Vol 52 (2) ◽  
pp. 329-334 ◽  
Author(s):  
Saleh H. Sedrani

1. The effects of vitamin D3(D3) on serum levels of 1, 25-dihydroxyvitamin D3(1, 25(OH)2D3), ionic calcium, total Ca and phosphorus in chicks were studied from the time of hatching until sexual maturity.2. Chicks fed on a diet low in D3showed a serum level of 1, 25(OH)2D3higher than that in chicks on a normal-D3diet, for both sexes and at any given age.3. A dramatic increase in the serum level of 1, 25(OH)2D3occurred in female birds approaching sexual maturity and in laying hens raised on the low-D3diet the level was five times that of their counterparts raised on a normal-D3diet.4. Theserum 1, 25(OH)2D3levelin adultmalesin thelow-D3groups wasseven timesthatofthoseon thenormal-D3diet.5. The serum level of 25-hydroxyvitamin D3remained relatively unchanged at weeks 2 and 15 in birds on a low D3intake as well as in those fed on a normal-D3diet. Nevertheless, the levels of 25-hydroxyvitamin D3were different between the two groups.6. No significant change was observed in the level of ionized serum Ca in relation to dietary regimen, but there was an increase in total Ca concentration in females with the onset of reproduction.7. The serum P level decreased gradually with age, reaching a minimum value 3 and 8 weeks before laying commenced in the groups on low- and normal-D3diets respectively. An increase was observed when the hens began laying.8. Chicks adapted to a low-D3diet by elevation of their plasma level of 1, 25(OH)2D3. The mechanism by which this is achieved is not known, but the results suggest that parathyroid hormone, Ca and P are unlikely to play roles in the adaptive increase in the level of 1, 25(OH)2D3in the blood of chicks given a minimal amount of D3. The possibility that the rate of degradation of 1, 25(OH)2D3is greatly reduced under these conditions cannot be excluded and this could account for the level of this metabolite in those birds.


Sign in / Sign up

Export Citation Format

Share Document